PMID- 31695493
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220411
IS  - 1179-1322 (Print)
IS  - 1179-1322 (Electronic)
IS  - 1179-1322 (Linking)
VI  - 11
DP  - 2019
TI  - Clinical And Imageological Features Of Lung Squamous Cell Carcinoma With EGFR 
      Mutations.
PG  - 9017-9024
LID - 10.2147/CMAR.S223021 [doi]
AB  - PURPOSE: To analyze the distribution of epidermal growth factor receptor (EGFR) 
      mutations; characterize the clinical and imageological features of lung squamous 
      cell carcinoma (LSCC) in a large population of patients; and assess correlations 
      between clinical and imageological characteristics and clinical outcomes of LSCC 
      patients harboring EGFR mutations. PATIENTS AND METHODS: Three pathologists 
      retrospectively evaluated the morphological and immunohistochemical data of 2,322 
      patients with LSCC resected between February 2013 and December 2017. Data on the 
      distribution of EGFR mutations and the clinical and imageological characteristics 
      of the patients were retrospectively collected. Correlations between the EGFR 
      mutation status and clinical outcomes were evaluated using univariate and 
      multivariate analyses. RESULTS: EGFR mutations were found in 3.4% of patients 
      with LSCC and predominantly in female and non-smoking patients. Tumor lesions in 
      patients with EGFR-positive mutations were more irregularly shaped than those in 
      patients with EGFR-negative mutations (P = 0.045). In non-smoking patients with 
      LSCC, the proportion of marked spiculation was significantly higher in the 
      EGFR-positive group than in the EGFR-negative group (P = 0.043). No significant 
      difference in recurrence-free survival was noted between LSCC patients harboring 
      EGFR-positive and those harboring EGFR-negative mutations. No difference in 
      metastases was observed between the EGFR-positive and EGFR-negative cohorts. 
      CONCLUSION: Female gender, non-smoking habit, irregularly shaped tumor, and 
      marked spiculation might predict the presence of EGFR mutations in LSCC. The 
      administration of tyrosine kinase inhibitors to patients with LSCC after 
      screening for EGFR mutations based on their clinical and imageological features 
      would likely result in a population with a greater sensitivity to afatinib.
CI  - (c) 2019 Gao et al.
FAU - Gao, Xuejuan
AU  - Gao X
AD  - Department of Physics, Xiamen University, Xiamen, People's Republic of China.
FAU - Zhu, Junjie
AU  - Zhu J
AD  - Department of Thoracic Surgery, Shanghai Pulmonary Hospital Affiliated to Tongji 
      University, Shanghai, People's Republic of China.
FAU - Chen, Linsong
AU  - Chen L
AD  - Department of Thoracic Surgery, Shanghai Pulmonary Hospital Affiliated to Tongji 
      University, Shanghai, People's Republic of China.
FAU - Jiang, Yan
AU  - Jiang Y
AD  - Department of Thoracic Surgery, Shanghai Pulmonary Hospital Affiliated to Tongji 
      University, Shanghai, People's Republic of China.
FAU - Zhou, Xiao
AU  - Zhou X
AD  - Department of Thoracic Surgery, Shanghai Pulmonary Hospital Affiliated to Tongji 
      University, Shanghai, People's Republic of China.
FAU - Shuai, Jianwei
AU  - Shuai J
AD  - Department of Physics, Xiamen University, Xiamen, People's Republic of China.
AD  - State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell 
      Signaling Network, Xiamen University, Xiamen, People's Republic of China.
FAU - Zhao, Yanfeng
AU  - Zhao Y
AD  - Department of Thoracic Surgery, Shanghai Pulmonary Hospital Affiliated to Tongji 
      University, Shanghai, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20191021
PL  - New Zealand
TA  - Cancer Manag Res
JT  - Cancer management and research
JID - 101512700
PMC - PMC6814869
OTO - NOTNLM
OT  - EGFR mutation
OT  - imageological feature
OT  - lung squamous cell carcinoma
OT  - recurrence-free survival
COIS- The authors report no conflicts of interest in this work.
EDAT- 2019/11/07 06:00
MHDA- 2019/11/07 06:01
PMCR- 2019/10/21
CRDT- 2019/11/08 06:00
PHST- 2019/07/12 00:00 [received]
PHST- 2019/09/18 00:00 [accepted]
PHST- 2019/11/08 06:00 [entrez]
PHST- 2019/11/07 06:00 [pubmed]
PHST- 2019/11/07 06:01 [medline]
PHST- 2019/10/21 00:00 [pmc-release]
AID - 223021 [pii]
AID - 10.2147/CMAR.S223021 [doi]
PST - epublish
SO  - Cancer Manag Res. 2019 Oct 21;11:9017-9024. doi: 10.2147/CMAR.S223021. 
      eCollection 2019.